Lu L, Xiao M, Li Z H, Jolliffe L K, Jones S, Broxmeyer H E, Weich N
Department of Medicine (Hematology/Oncology), Indiana University School of Medicine, Indianapolis 46202-5121, USA.
Exp Hematol. 1995 Sep;23(10):1130-4.
Human interleukin-3/erythropoietin (IL-3/Epo) fusion protein have been constructed, expressed, and tested for biological activity. These fusion proteins were previously shown to be active on erythroid progenitors (BFU-E) from unseparated human bone marrow. We evaluated if these fusion proteins could stimulate erythroid and multipotential progenitor cells directly at the single-cell level. Two IL-3/Epo fusion proteins containing short (SL-3E, two amino acids) and long (LL-3E, 23 amino acids) linker sequences as well as a short linker Epo/IL-3 sequence (SL-E3, three amino acids) were tested. Highly enriched CD34 or BFU-E enriched CD34 CD33- cells from human umbilical cord blood or CD34 HLA-DR+CD33- cells from normal adult bone marrow were sorted as single cells into single wells. The combination of Epo plus IL-3 synergized to enhance the proliferation of BFU-E and multipotential progenitors (CFU-GEMM) in comparison to the individual effects of these cytokines. The three fusion proteins also enhanced proliferation of BFU-E and CFU-GEMM at the single-cell level and were at least as active as the combination of Epo and IL-3, demonstrating that IL-3/Epo fusion proteins directly stimulate proliferation of BFU-E and CFU-GEMM and that biological activity of IL-3 and Epo in vitro can be maintained when these proteins are fused. The activity of the combination of Epo and IL-3 or the fusion proteins was partially neutralized by preincubation with monoclonal antibodies to either Epo or IL-3 and was neutralized by greater than 90% by the combination of both antibodies, suggesting that the Epo and IL-3 components of the fusion proteins were both involved in the enhancing activity of these proteins. Additionally, use of monoclonal antibody to the human Epo receptor completely blocked the stimulating/enhancing activity of Epo alone, Epo plus IL-3, or the fusion proteins for stimulation of colony formation by BFU-E and CFU-GEMM but not for granulocyte-macrophage progenitors (CFU-GM), suggesting that the enhancing effects of the fusion proteins are most likely mediated, at least in part, by the Epo receptor.
人白细胞介素-3/促红细胞生成素(IL-3/Epo)融合蛋白已被构建、表达并进行了生物活性测试。这些融合蛋白先前已被证明对未分离的人骨髓中的红系祖细胞(BFU-E)具有活性。我们评估了这些融合蛋白是否能在单细胞水平直接刺激红系和多能祖细胞。测试了两种含有短(SL-3E,两个氨基酸)和长(LL-3E,23个氨基酸)连接序列的IL-3/Epo融合蛋白以及一种短连接子Epo/IL-3序列(SL-E3,三个氨基酸)。将来自人脐带血的高度富集的CD34或富集BFU-E的CD34 CD33-细胞或来自正常成人骨髓的CD34 HLA-DR+CD33-细胞作为单细胞分选到单个孔中。与这些细胞因子的单独作用相比,Epo加IL-3的组合协同增强了BFU-E和多能祖细胞(CFU-GEMM)的增殖。这三种融合蛋白在单细胞水平也增强了BFU-E和CFU-GEMM的增殖,并且至少与Epo和IL-3的组合一样活跃,表明IL-3/Epo融合蛋白直接刺激BFU-E和CFU-GEMM的增殖,并且当这些蛋白融合时,IL-3和Epo在体外的生物活性可以维持。Epo和IL-3的组合或融合蛋白的活性通过与抗Epo或抗IL-3单克隆抗体预孵育而部分中和,并且通过两种抗体的组合中和超过90%,这表明融合蛋白的Epo和IL-3成分都参与了这些蛋白的增强活性。此外,使用抗人Epo受体单克隆抗体完全阻断了Epo单独、Epo加IL-3或融合蛋白对BFU-E和CFU-GEMM集落形成的刺激/增强活性,但对粒细胞-巨噬细胞祖细胞(CFU-GM)没有阻断作用,这表明融合蛋白的增强作用至少部分可能是由Epo受体介导的。